Hill-Rom Holdings, Inc. (NYSE:HRC) – Analysts at KeyCorp raised their FY2019 earnings estimates for Hill-Rom in a research note issued to investors on Wednesday. KeyCorp analyst M. Mishan now expects that the medical technology company will earn $5.08 per share for the year, up from their prior estimate of $4.70. KeyCorp currently has a “Buy” rating and a $97.00 target price on the stock.

HRC has been the subject of a number of other reports. Zacks Investment Research raised shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $99.00 price target for the company in a research report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $105.00 price target (up from $90.00) on shares of Hill-Rom in a research report on Tuesday. Barclays reissued a “buy” rating and issued a $100.00 price target on shares of Hill-Rom in a research report on Wednesday, January 10th. Raymond James Financial raised shares of Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 price target for the company in a research report on Wednesday, January 3rd. Finally, Morgan Stanley cut shares of Hill-Rom from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 2nd. They noted that the move was a valuation call. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $95.38.

Shares of Hill-Rom (NYSE:HRC) traded up $1.50 during mid-day trading on Friday, hitting $89.30. 512,759 shares of the company were exchanged, compared to its average volume of 371,576. The company has a current ratio of 1.77, a quick ratio of 1.34 and a debt-to-equity ratio of 1.55. The firm has a market capitalization of $5,779.08, a P/E ratio of 44.87, a P/E/G ratio of 1.55 and a beta of 1.19. Hill-Rom has a 12-month low of $57.18 and a 12-month high of $89.64.

Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, November 3rd. The medical technology company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.05. The firm had revenue of $738.30 million during the quarter, compared to the consensus estimate of $731.10 million. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The company’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.18 earnings per share.

The business also recently declared a quarterly dividend, which was paid on Friday, December 29th. Investors of record on Friday, December 15th were given a $0.18 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $0.72 dividend on an annualized basis and a yield of 0.81%. Hill-Rom’s dividend payout ratio (DPR) is presently 36.18%.

In related news, CEO John J. Greisch sold 125,241 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $82.59, for a total value of $10,343,654.19. Following the completion of the sale, the chief executive officer now directly owns 280,851 shares of the company’s stock, valued at $23,195,484.09. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $82.99, for a total transaction of $82,990.00. Following the completion of the sale, the senior vice president now directly owns 1,066 shares of the company’s stock, valued at $88,467.34. The disclosure for this sale can be found here. Over the last three months, insiders sold 226,241 shares of company stock valued at $18,708,644. 2.20% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the company. Seven Eight Capital LP purchased a new stake in shares of Hill-Rom in the second quarter valued at about $127,000. CAPROCK Group Inc. purchased a new stake in shares of Hill-Rom in the fourth quarter valued at about $211,000. Citigroup Inc. raised its holdings in shares of Hill-Rom by 21.1% in the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after buying an additional 433 shares during the last quarter. DekaBank Deutsche Girozentrale raised its holdings in shares of Hill-Rom by 101.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock valued at $204,000 after buying an additional 1,367 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Hill-Rom in the third quarter valued at about $207,000. 81.92% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “KeyCorp Weighs in on Hill-Rom Holdings, Inc.’s FY2019 Earnings (HRC)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/keycorp-weighs-in-on-hill-rom-holdings-inc-s-fy2019-earnings-hrc/1815698.html.

About Hill-Rom

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Earnings History and Estimates for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.